MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2020 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
4.28 M |
Market Cap[1] |
$ 269 M |
EBITDA (LTM) |
$ -121 M |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
-23.11 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Praxis Precision Medicines
PRAX
|
$ 337.69 | 1.42 % | $ 7.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.78 | 0.53 % | $ 291 M | Nasdaq Global Select Market | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.31 | -5.07 % | $ 138 M | Nasdaq Global Market |  Niderland |
 |
Ocular Therapeutix
OCUL
|
$ 6.62 | -3.36 % | $ 1.24 B | Nasdaq Global Select Market | USA |
 |
PolyPid Ltd.
PYPD
|
$ 6.3 | 0.96 % | $ 103 M | Nasdaq Global Select Market |  Israel |
 |
Outlook Therapeutics
OTLK
|
$ 0.46 | -0.84 % | $ 16 M | Nasdaq Global Select Market | USA |
 |
uniQure N.V.
QURE
|
$ 22.7 | -0.39 % | $ 1.31 B | Nasdaq Global Select Market | Niderland |
 |
Ultragenyx Pharmaceutical
RARE
|
$ 16.13 | -1.71 % | $ 1.59 B | Nasdaq Global Select Market,SPB | USA |
 |
Rafael Holdings
RFL
|
$ 1.11 | 2.45 % | $ 57 M | NYSE | USA |
 |
REGENXBIO
RGNX
|
$ 7.66 | -5.08 % | $ 395 M | Nasdaq Global Select Market,SPB | USA |
 |
Rigel Pharmaceuticals
RIGL
|
$ 43.83 | 4.22 % | $ 788 M | Nasdaq Global Select Market | USA |
 |
SELLAS Life Sciences Group
SLS
|
$ 8.38 | -2.39 % | $ 914 M | Nasdaq Capital Market | USA |
 |
Celsion Corporation
CLSN
|
- | -6.63 % | $ 13.9 M | Nasdaq Capital Market | USA |
 |
Генетико
GECO
|
- | - | - | MOEX |  Russia |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Tenax Therapeutics
TENX
|
$ 1.69 | -5.34 % | $ 66.3 M | Nasdaq Global Select Market | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market |  Germany |
 |
BiondVax Pharmaceuticals Ltd.
BVXV
|
- | 0.74 % | $ 768 M | Nasdaq Capital Market | Israel |
 |
Abcam plc
ABCM
|
- | - | $ 4.9 B | Nasdaq Global Select Market |  Britain |
 |
Rezolute
RZLT
|
$ 4.01 | 3.83 % | $ 417 M | Nasdaq Capital Market | USA |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
Tiziana Life Sciences PLC
TLSA
|
$ 0.61 | -8.44 % | $ 65.1 M | Nasdaq Global Market | Britain |
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | Germany |
 |
Affimed N.V.
AFMD
|
- | -34.95 % | $ 21.5 M | Nasdaq Global Select Market,SPB | Germany |
 |
AnPac Bio-Medical Science Co., Ltd.
ANPC
|
- | -1.58 % | $ 28.1 M | Nasdaq Global Market | China |
 |
Celyad Oncology SA
CYAD
|
- | - | $ 12.5 M | Nasdaq Global Market |  Belgium |
 |
Seer
SEER
|
$ 1.62 | -3.57 % | $ 89.7 M | Nasdaq Global Select Market | USA |
 |
Gracell Biotechnologies
GRCL
|
- | - | $ 3.37 B | Nasdaq Global Select Market | China |
 |
Shattuck Labs
STTK
|
$ 4.86 | -2.71 % | $ 338 M | Nasdaq Global Select Market | USA |
|
Silence Therapeutics plc
SLN
|
$ 19.78 | 0.15 % | $ 2.8 B | Nasdaq Global Select Market | Britain |
 |
Stoke Therapeutics
STOK
|
$ 27.16 | -1.98 % | $ 1.61 B | Nasdaq Global Select Market,SPB | USA |
 |
Sutro Biopharma
STRO
|
$ 10.08 | -5.0 % | $ 85.7 M | Nasdaq Global Select Market | USA |
 |
Soligenix
SNGX
|
$ 0.32 | -6.35 % | $ 1.66 M | Nasdaq Capital Market | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
$ 42.54 | -1.0 % | $ 48.7 B | NYSE | Israel |
 |
China SXT Pharmaceuticals
SXTC
|
$ 2.99 | -3.55 % | $ 2.03 M | Nasdaq Global Select Market | China |
 |
Spruce Biosciences
SPRB
|
$ 46.36 | -6.04 % | $ 35.5 M | Nasdaq Global Select Market | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
$ 20.9 | -0.9 % | $ 33 B | NYSE |  Japan |
 |
Supernus Pharmaceuticals
SUPN
|
$ 28.77 | 4.15 % | $ 1.62 B | Nasdaq Global Select Market,SPB | USA |
 |
Galapagos NV
GLPG
|
- | - | $ 1.83 B | Nasdaq Global Select Market | Belgium |
 |
Savara
SVRA
|
$ 4.92 | -2.57 % | $ 1.09 B | Nasdaq Global Select Market | USA |
 |
Teligent, Inc.
TLGT
|
- | -13.85 % | $ 16.1 M | Nasdaq Global Select Market | USA |
 |
Viela Bio, Inc.
VIE
|
- | - | $ 2.91 B | Nasdaq Global Select Market | USA |
 |
TG Therapeutics
TGTX
|
$ 64.27 | 1.4 % | $ 9.28 B | Nasdaq Capital Market | USA |
 |
Aphria Inc.
APHA
|
- | -0.45 % | $ 4.87 B | Nasdaq Global Select Market |  Canada |
 |
Aerpio Pharmaceuticals, Inc.
ARPO
|
- | -0.90 % | $ 104 M | Nasdaq Capital Market | USA |
 |
Chiasma, Inc.
CHMA
|
- | -6.00 % | $ 238 M | Nasdaq Global Select Market | USA |
 |
Trevi Therapeutics
TRVI
|
$ 14.92 | -2.55 % | $ 2.01 B | Nasdaq Global Market | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.